TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18824643

Group type: EXPERIMENTAL
Intervention: Eplerenone (25 to 50 mg/d)
Number of subjects: 6632

Group type: COMPARATOR
Intervention: Standard therapy (placebo)
Number of subjects: 6632
Study: 16078134

Group type: EXPERIMENTAL
Intervention: Stochastic differential equations (SDEs) in population PK/PD modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended Kalman Filter (EKF)
Number of subjects: 0
Study: 12166709

Group type: EXPERIMENTAL
Intervention: Clasp-retained dentures
Number of subjects: 181

Group type: COMPARATOR
Intervention: Conical crown-retained dentures (CC)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Parallel-sided retained dentures (PS)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Repair costs for clasp-retained dentures
Number of subjects: 181

Group type: COMPARATOR
Intervention: Repair costs for double crown systems
Number of subjects: 181
Study: 10597783

Group type: EXPERIMENTAL
Intervention: APV 1200 mg with 3TC/ZDV
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: APV 900 mg with 3TC/ZDV
Number of subjects: 84

Group type: COMPARATOR
Intervention: 3TC/ZDV with 1050 mg APV added at week 12
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: APV 1050 mg with 3TC/ZDV
Number of subjects: 84
Study: 8521562

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg CR
Number of subjects: 30
Study: 1958433

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cholestyramine
Number of subjects: 23
Study: 31094251

Group type: EXPERIMENTAL
Intervention: 10% velocity loss threshold
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20% velocity loss threshold
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 30% velocity loss threshold
Number of subjects: 16
Study: 30826975

Group type: EXPERIMENTAL
Intervention: Social network descriptive sexual norms and behaviors
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Egos' norms of condomless sex with primary partners
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Egos' norms of condomless sex with casual partners
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Egos' norms of giving money/drugs for sex
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Egos' norms of receiving money/drugs for sex
Number of subjects: 232
Study: 28522204

Group type: EXPERIMENTAL
Intervention: peg‐IFN plus adefovir 10 mg/day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: peg‐IFN plus tenofovir 245 mg/day
Number of subjects: 151

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 151
Study: 25407377

Group type: EXPERIMENTAL
Intervention: Peer leader use (networked condition)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 525
Study: 24330215

Group type: EXPERIMENTAL
Intervention: Non-pharmacological staged interventions
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 64
Study: 21246176

Group type: EXPERIMENTAL
Intervention: Blue-enriched light (8000 K)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Warm light (4000 K)
Number of subjects: 54
Study: 19177141

Group type: EXPERIMENTAL
Intervention: Mild regimen (10-30 g per day of clobetasol propionate cream, tapering over 4 months)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Standard regimen (40 g per day of clobetasol propionate cream, tapering over 12 months)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Mild regimen
Number of subjects: 312

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 312
Study: 17325296

Group type: EXPERIMENTAL
Intervention: Raw garlic
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Powdered garlic supplement
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Aged garlic extract supplement
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 14968388

Group type: EXPERIMENTAL
Intervention: Anterior VentroFix instrumentation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Posterior Universal Spine System stabilization
Number of subjects: 22
Study: 11788172

Group type: EXPERIMENTAL
Intervention: Garlic tablet (Garlet) 800mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo 800mg/day
Number of subjects: 100
Study: 9547667

Group type: EXPERIMENTAL
Intervention: Cognitive group treatment program (CT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Behavior therapy weight loss program (BT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 62
Study: 7979426

Group type: COMPARATOR
Intervention: TAE group (transcatheter arterial embolization)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: TAE-RV group (arterial infusion chemotherapy through implantable port after TAE)
Number of subjects: 75

Group type: COMPARATOR
Intervention: One-shot group (one-shot arterial infusion chemotherapy)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: RV group (arterial infusion chemotherapy through implantable port)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: RV group
Number of subjects: 75
Study: 3052974

Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone acetate
Number of subjects: 127

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 127
Study: 31342902

Group type: EXPERIMENTAL
Intervention: Spanish-language, culturally adapted, individually tailored, internet-based PA intervention
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Goal-setting features
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: PA tips
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: PA reports
Number of subjects: 205

Group type: COMPARATOR
Intervention: Spanish language, internet-based, Wellness Contact Control
Number of subjects: 205
Study: 28699561

Group type: EXPERIMENTAL
Intervention: Camino Verde intervention using the SEPA approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26405092

Group type: EXPERIMENTAL
Intervention: Dalotuzumab 10mg/kg weekly (arm A)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Dalotuzumab 7.5mg/kg every alternate week (arm B)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo (arm C)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: High IGF-1 mRNA tumors in arm A
Number of subjects: 344

Group type: COMPARATOR
Intervention: High IGF-1 mRNA tumors in arm C
Number of subjects: 344
Study: 23138388

Group type: EXPERIMENTAL
Intervention: Free-breathing CCTA
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard breath-holding CCTA
Number of subjects: 74
Study: 21205942

Group type: EXPERIMENTAL
Intervention: Simple stenting (provisional T-stenting)
Number of subjects: 913

Group type: COMPARATOR
Intervention: Complex stenting techniques (crush, culotte, T-stenting)
Number of subjects: 913

Group type: COMPARATOR
Intervention: Complex stenting techniques
Number of subjects: 913
Study: 18447941

Group type: EXPERIMENTAL
Intervention: 10 mg/day of sugar cane policosanols (SCP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo incorporated in margarine
Number of subjects: 21
Study: 17192538

Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine (lapatinib at a dose of 1250 mg per day continuously plus capecitabine at a dose of 2000 mg per square meter on days 1 through 14 of a 21-day cycle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine alone (at a dose of 2500 mg per square meter on days 1 through 14 of a 21-day cycle)
Number of subjects: 0
Study: 14529983

Group type: EXPERIMENTAL
Intervention: Muscle-sparing thoracotomy (group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard posterolateral thoracotomy (group I)
Number of subjects: 60
Study: 10914847

Group type: EXPERIMENTAL
Intervention: 200 mg hydroxychloroquine sulfate daily (Group A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 400 mg hydroxychloroquine sulfate daily (Group B)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 23
Study: 8980924

Group type: EXPERIMENTAL
Intervention: 3 x 50 mg of amitriptyline (AT) daily for 6 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3 x 25 mg of amitriptyline (AT) daily for 6 weeks
Number of subjects: 15
Study: 1419760

Group type: EXPERIMENTAL
Intervention: Bath-water-delivered 8-methoxypsoralen (bath 8-MOP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral 8-methoxypsoralen (oral 8-MOP)
Number of subjects: 44
Study: 3917496

Group type: EXPERIMENTAL
Intervention: Vamin 7%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Travasol 10% blend B
Number of subjects: 0
Study: 31177055

Group type: EXPERIMENTAL
Intervention: Human donor milk
Number of subjects: 29

Group type: COMPARATOR
Intervention: Formula milk
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Human donor milk with >60 kcal/100 mL
Number of subjects: 29
Study: 29512041

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 54

Group type: COMPARATOR
Intervention: Light physical exercise
Number of subjects: 54
Study: 26343171

Group type: EXPERIMENTAL
Intervention: Peer-led self-efficacy-enhanced wheelchair training program (WheelSee)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 24293632

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus, followed by continuous infusion of 100 mg/h for patients >70 kg or 70 mg/h for patients <70 kg over 48 h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 22520119

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV)
Number of subjects: 2036

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2036
Study: 20212196

Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 1636

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1636
Study: 17010979

Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 16228196

Group type: EXPERIMENTAL
Intervention: Ketamine (bolus of 0.23 mg/kg and infusion of 0.65 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo normal saline
Number of subjects: 10
Study: 12167390

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 9802525

Group type: EXPERIMENTAL
Intervention: Ethanol (0.6 g/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7639806

Group type: EXPERIMENTAL
Intervention: CD4 monoclonal antibody (MAb) cM‐T412
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2707917

Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg, three times a day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Digoxin (control group)
Number of subjects: 58
Study: 357303

Group type: EXPERIMENTAL
Intervention: Ammonium ion‐specific electrode system for blood urea nitrogen analysis
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of urea in dialysate fluid
Number of subjects: 187
Study: 30669717

Group type: EXPERIMENTAL
Intervention: Jinghuaweikang capsules (160 mg, three times a day) + Quadruple therapy (esomeprazole 20 mg, twice a day; pectin bismuth 200 mg, three times a day; amoxicillin 1000 mg, twice a day; clarithromycin 500 mg, twice a day)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Jinghuaweikang capsules (160 mg, three times a day) + Quadruple therapy (esomeprazole 20 mg, twice a day; bismuth pectin 200 mg, three times a day; amoxicillin 1000 mg, twice a day; furazolidone 100 mg, twice a day)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Quadruple therapy (esomeprazole 20 mg, twice a day; pectin bismuth 200 mg, three times a day; amoxicillin 1000 mg, twice a day; clarithromycin 500 mg, twice a day)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Quadruple therapy (esomeprazole 20 mg, twice a day; bismuth pectin 200 mg, three times a day; amoxicillin 1000 mg, twice a day; furazolidone 100 mg, twice a day)
Number of subjects: 455
Study: 29596646

Group type: EXPERIMENTAL
Intervention: OBMT therapy (bismuth, metronidazole, tetracycline with omeprazole)
Number of subjects: 384

Group type: COMPARATOR
Intervention: OBAC therapy (bismuth, omeprazole, amoxicillin, and clarithromycin)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Both OBMT and OBAC therapies
Number of subjects: 384
Study: 26498268

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (CBT) for 11 weeks
Number of subjects: 133

Group type: COMPARATOR
Intervention: Discussion group (active control)
Number of subjects: 133
Study: 25321869

Group type: EXPERIMENTAL
Intervention: Cervical total disc replacement (CTDR)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Cervical total disc replacement (CTDR) compared with ACDF
Number of subjects: 330
Study: 23262475

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of 1.5 g of magnesium sulphate followed by an infusion of 12 g in 24 h
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo administered according to the same schedule as the treatment group
Number of subjects: 216
Study: 21055665

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 10 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 27
Study: 17592101

Group type: EXPERIMENTAL
Intervention: Portion control plate for 6 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care (dietary teaching)
Number of subjects: 130
Study: 16302041

Group type: EXPERIMENTAL
Intervention: Amodiaquine + Artesunate (AQ+AS)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Coartemether (Artemether-Lumefantrine)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulfadoxine-Pyrimethamine (AQ+SP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Amodiaquine Monotherapy (AQ)
Number of subjects: 180
Study: 12476475

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 80
Study: 10190651

Group type: COMPARATOR
Intervention: Normotensives
Number of subjects: 289
Study: 7672026

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mg s.c.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2369230

Group type: EXPERIMENTAL
Intervention: Acute plasmapheresis with hemofiltration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acute plasmapheresis with Cell Saver
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Platelet-poor plasma
Number of subjects: 60
Study: 7218312

Group type: EXPERIMENTAL
Intervention: Clinical librarian service
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control settings
Number of subjects: 8
Study: 31468714

Group type: EXPERIMENTAL
Intervention: Revefenacin 175 µg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revefenacin 700 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (open-label)
Number of subjects: 0
Study: 30668840

Group type: COMPARATOR
Intervention: Basal diet (Glu calculated at 2.68%)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: L-glutamic acid inclusion levels: 2.88%
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: L-glutamic acid inclusion levels: 3.08%
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: L-glutamic acid inclusion levels: 3.28%
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: L-glutamic acid inclusion levels: 3.48%
Number of subjects: 240

Group type: COMPARATOR
Intervention: L-glutamic acid inclusion levels: 2.68%
Number of subjects: 240
Study: 28121892

Group type: EXPERIMENTAL
Intervention: Perforator-based interposition flaps
Number of subjects: 30

Group type: COMPARATOR
Intervention: Full-thickness skin grafts
Number of subjects: 30
Study: 26312445

Group type: EXPERIMENTAL
Intervention: Intra-articular injections with ropivacaine (100 mg) and ketorolac (15 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 80
Study: 24382594

Group type: EXPERIMENTAL
Intervention: Supported employment plus cognitive remediation
Number of subjects: 175

Group type: COMPARATOR
Intervention: Supported employment
Number of subjects: 175
Study: 22122202

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 microg
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 20364555

Group type: EXPERIMENTAL
Intervention: Siriraj Leg Lock (SLL) brace
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 17645430

Group type: EXPERIMENTAL
Intervention: MET/CBT with CM
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: MET/CBT without CM
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: DC with CM
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: DC without CM
Number of subjects: 136
Study: 16287791

Group type: EXPERIMENTAL
Intervention: Frequent condom use (greater than 75% of sexual acts)
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Less frequent condom use (0% to 25% and 25% to 75% of sexual acts)
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Condom use
Number of subjects: 1843
Study: 12153608

Group type: EXPERIMENTAL
Intervention: GH 1.7 IU/m2/day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: GH 0.5 IU/m2/day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: GH 1.0 IU/m2/day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 10209831

Group type: EXPERIMENTAL
Intervention: Shock energy programmed at twice DFT+
Number of subjects: 176

Group type: COMPARATOR
Intervention: Shock energy at maximum output (34 J)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 176
Study: 7796255

Group type: EXPERIMENTAL
Intervention: initial family assessment; child and family seen together
Number of subjects: 100

Group type: COMPARATOR
Intervention: individual assessment; child and parents seen in parallel
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: initial family interview
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: long term therapy
Number of subjects: 100
Study: 2394504

Group type: EXPERIMENTAL
Intervention: High-fat diet (40% calories from fat) for 4 menstrual cycles
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-fat diet (20% calories from fat) for 4 menstrual cycles
Number of subjects: 31
Study: 7004635

Group type: EXPERIMENTAL
Intervention: Combination treatment (doxorubicin every 21 days, cyclophosphamide daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Fixed-rotation schedule (doxorubicin every 42 days, cyclophosphamide for 21 days of the 42-day cycle)
Number of subjects: 96
Study: 30021811

Group type: EXPERIMENTAL
Intervention: Higher cord blood 25OHD at birth (>31 ng/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cord blood 25OHD levels >31 ng/mL
Number of subjects: 0
Study: 28224946

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25850540

Group type: EXPERIMENTAL
Intervention: Vibrated group (VG) - mechanical vibration applied on quadriceps muscles, 10 min, three times a day for three consecutive days.
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (CG) - placebo vibratory stimulation (sham treatment).
Number of subjects: 350
Study: 23650295

Group type: EXPERIMENTAL
Intervention: Inconsolable crying >20 minutes per day
Number of subjects: 587

Group type: COMPARATOR
Intervention: Colic (defined by Wessel's criteria)
Number of subjects: 587
Study: 21899766

Group type: EXPERIMENTAL
Intervention: One-page ADR information letters administered at three occasions during 2008 to all physicians and nurses in the intervention units
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 151
Study: 18458922

Group type: EXPERIMENTAL
Intervention: Goosestep training without forcefully striking the ground
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Goosestep training with forcefully striking the ground
Number of subjects: 40
Study: 17383520

Group type: EXPERIMENTAL
Intervention: Computer-based video instruction (CBVI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent expert feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Summary expert feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 0
Study: 16799399

Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg daily and fenofibrate 160 mg daily (PPAR group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: glibenclamide 5 mg daily and atorvastatin 10 mg daily (non‐PPAR group)
Number of subjects: 24
Study: 14709198

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intensive subcutaneous insulin therapy (ISIT)
Number of subjects: 23
Study: 10815784

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 8781013

Group type: EXPERIMENTAL
Intervention: Immediate Intervention (physician-delivered brief quit-smoking advice and counseling)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Delayed Intervention (usual care)
Number of subjects: 659
Study: 1531044

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg intravenous dose
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg oral dose
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 3
Study: 6435483

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular fentanyl injection
Number of subjects: 0
Study: 31234962

Group type: EXPERIMENTAL
Intervention: HealthMap trial (online self-management program)
Number of subjects: 728
Study: 28056076

Group type: EXPERIMENTAL
Intervention: Laerdal QCPR® (QCPR group)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard instructor-based feedback (SF group)
Number of subjects: 144